Insider · CIK 0001924188
Eduardo Rene Salas
director
Files at ADMA (ADMA BIOLOGICS, INC.), ITCI (Intra-Cellular Therapies, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,690 | $0.00 | $0 | 21,579 | Feb 11, 2026 |
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +17,730 | $0.00 | $0 | 17,730 | Feb 11, 2026 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Common Stock | -1,567 | $132.00 | $207k | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -16,757 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -7,009 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,889 | $0.00 | $0 | 10,889 | Feb 21, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (right to buy)derivative | +16,279 | $0.00 | $0 | 16,279 | Feb 21, 2025 |
| Dec 30, 2024 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (right to buy)derivative | +20,011 | $0.00 | $0 | 20,011 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.